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Summary
Background Many ways of preventing HIV infection have been proposed and more are being developed. We sought to 
construct a strategic approach to HIV prevention that would use limited resources to achieve the greatest possible 
prevention impact through the use of interventions available today and in the coming years.
Methods We developed a deterministic compartmental model of heterosexual HIV transmission in South Africa and 
formed assumptions about the costs and eﬀ ects of a range of interventions, encompassing the further scale-up of 
existing interventions (promoting condom use, male circumcision, early antiretroviral therapy [ART] initiation for all 
[including increased HIV testing and counselling activities], and oral pre-exposure prophylaxis [PrEP]), the introduction 
of new interventions in the medium term (oﬀ ering intravaginal rings, long-acting injectable antiretroviral drugs) and 
long term (vaccine, broadly neutralising antibodies [bNAbs]). We examined how available resources could be allocated 
across these interventions to achieve maximum impact, and assessed how this would be aﬀ ected by the failure of the 
interventions to be developed or scaled up.
Findings If all interventions are available, the optimum mix would place great emphasis on the following: scale-up of male 
circumcision and early ART initiation with outreach testing, as these are available immediately and assumed to be low 
cost and highly eﬃ  cacious; intravaginal rings targeted to sex workers; and vaccines, as these can achieve a large eﬀ ect if 
scaled up even if imperfectly eﬃ  cacious. The optimum mix would rely less on longer term developments, such as long-
acting antiretroviral drugs and bNAbs, unless the costs of these reduced. However, if impossible to scale up existing 
interventions to the extent assumed, emphasis on oral PrEP, intravaginal rings, and long-acting antiretroviral drugs would 
increase. The long-term eﬀ ect on the epidemic is most aﬀ ected by scale-up of existing interventions and the successful 
development of a vaccine.
Interpretation With current information, a strategic approach in which limited resources are used to maximise 
prevention impact would focus on strengthening the scale-up of existing interventions, while pursuing a workable 
vaccine and developing other approaches that can be used if further scale-up of existing interventions is limited.
Funding Bill & Melinda Gates Foundation.
Copyright © Smith et al. Open Access article distributed under the terms of CC BY. 
Introduction
The AIDS response has had outstanding success in the 
development and global scale-up of antiretroviral therapy 
(ART).1 With a few exceptions, there has been less success 
in reducing the spread of the HIV epidemic.2–4 However, the 
sustainability of the response rests upon there being large 
reductions in new HIV infections in the coming years.5
To meet this challenge, prevention interventions have 
been the focus of much research and development 
investment; programmes are now in the fortunate 
position of having a range of interventions to consider, 
including male condoms, voluntary medical male 
circumcision (VMMC) services, increased HIV testing 
and initiation of ART for all diagnosed with HIV (early 
ART), and oral pre-exposure prophylaxis (PrEP). These 
interventions need to be prioritised for populations and 
groups at the greatest risk and who stand to beneﬁ t 
most.6–8 There is also a growing understanding of the 
barriers to impact that are faced. These barriers have 
been articulated as the prevention cascade (Hargreaves 
and colleagues,9 this issue) and include limitations in the 
supply of, demand for, and adherence to an intervention 
arising from logistic, structural, and behavioural factors. 
Arguably, innovative approaches might be able to allow 
these barriers to increasingly be overcome.
At the same time, there are many advances in the 
development of new technologies that oﬀ er new possible 
interventions to prevent HIV infections. In the medium 
term, intravaginal rings and long-acting injectable 
antiretroviral drugs might be eﬃ  cacious and acceptable 
to potential users.10–14 In the longer term, eﬀ ective 
transfusions of broadly neutralising antibodies (bNAbs), 
or a vaccine, might become available.15,16 These new 
technological developments oﬀ er promise, but it should 
be remembered that these too will have to overcome the 
same prevention cascade barriers as other interventions.
For programme planning and for determining 
investments in research and development, it is crucial to 
be able to establish priorities among this large portfolio. 
Usually, the value and probable eﬀ ect of each intervention 
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is considered separately. However, because they overlap 
in their functionality and the eﬀ ect of one intervention 
aﬀ ects that of others, a holistic perspective is needed to 
establish a coherent strategy for HIV prevention that 
maximises the reduction in HIV incidence and is aligned 
with information about the epidemic, and the potential 
risks, costs, and beneﬁ ts of new developments. To do 
this, researchers should investigate which con ﬁ guration 
of present and future interventions will maximise 
prevention with available resources, assess the 
contribution of each component to overall success to 
inform research and development priorities, and monitor 
how new information on the success of interventions (in 
scale-up or further development) informs the balance of 
the portfolio and the overall eﬀ ect.
To achieve these aims, we developed a model of the 
HIV epidemic in South Africa. We incorporated the 
extent of current intervention scale-up and simulated the 
cost and eﬀ ect of a wide portfolio of options for HIV 
prevention, encompassing the further scale-up of existing 
interventions and the introduction of interventions 
focused on new technological developments, to identify 
optimum allocations of resources.
Methods
Overview
We brieﬂ y describe the analysis framework, model 
design, and assumptions about interventions’ eﬀ ects and 
costs (further details are provided in the appendix). We 
began by enumerating all the potential interventions 
(existing and future technologies) that could be scaled up 
and formed assumptions about the nature of their use 
(coverage, timing, priority groups) in a range of scenarios 
(table 1).
We deﬁ ned three sets of scale-up assumptions that 
span the range of possible scale-up scenarios for each 
intervention (except for vaccination, which has only two): 
the constant scenario assumed no intro duction or 
additional scale-up of prevention interventions; the 
medium scenario characterised the degree of long-term 
scale-up that might be anticipated on the basis of current 
planning; and the maximum scenario determined the 
fullest possible extent to which those interventions could 
be deployed. The medium scenario is credible and is 
based on consultation with a working group of Bill & 
Melinda Gates Foundation staﬀ  for the development of 
each of these interventions (appendix p 13).
We characterised the optimum set of interventions 
across a wide range of assumptions for the budget 
available for HIV prevention. Next, we simulated the 
eﬀ ect and evaluated the total cost of implementing the 
medium scenario from 2016 to 2050. We then explored 
all possible permutations of the scale-up of the 
interventions (n=4374, from seven interventions with 
three possible coverage levels and one intervention with 
two levels) to determine if other conﬁ gurations of 
Research in context
Evidence before this study
Many empirical and modelling studies have investigated the 
eﬀ ect and cost-eﬀ ectiveness of diﬀ erent HIV prevention 
interventions, singly and in combination, and across diﬀ erent 
settings. More recently, modelling studies have done these 
analyses under the constraint of resource allocation—whereby 
multiple combinations of interventions are examined to 
understand the best way of spending a ﬁ xed budget. We 
searched PubMed for HIV prevention studies published 
between Jan 1, 2000, and Dec 31, 2015, with the terms “HIV 
prevention” AND (“budget allocation” OR “resource 
allocation”) AND (“model” OR “modeling” OR “modelling”). 
Our results included a 2013 systematic review of cost-
eﬀ ectiveness modelling studies of PrEP, which found that PrEP 
has the potential to be a cost-eﬀ ective addition to HIV 
prevention programmes in speciﬁ c settings, particularly when 
delivered to key populations at highest risk of HIV exposure. 
We identiﬁ ed 22 abstracts, of which 17 studies met our 
inclusion criteria of mathematical modelling studies. Most 
resource allocation models are from a health economics 
perspective with a short-term outlook, with only a few 
including a dynamic HIV transmission model (which account 
for future trends in the epidemic). Of two recent analyses 
including detailed economic and epidemiological information 
from Kenya and south India respectively, one shows the 
additional gains of geographical prioritisation of interventions 
by local epidemiology, and one shows that as budget levels 
increase, the optimum intervention strategy is to ﬁ rst increase 
intervention intensity before scaling up coverage. Other 
recent studies on new technologies highlight that long-acting 
PrEP for high-risk women could be cost-eﬀ ective and that 
even a medium-eﬃ  cacy vaccine could have a substantial 
impact on the epidemic. Resource allocation models are 
increasingly being developed and used at international and 
national levels to help guide HIV prevention policy.
Added value of this study
We analyse present and future interventions within the 
framework of optimum resource allocation using a synthesis of 
all available data. We ﬁ nd that scaling up existing interventions 
is the most cost-eﬀ ective way to stem new HIV infections in 
South Africa, with new technologies able to plug the gaps in 
cases where the predicted scale-ups are not possible.
Implications of all the available evidence
Our ﬁ ndings add to an increasing body of evidence that 
frontloading HIV prevention investments to maximise the use 
of interventions which are available now leads to the largest 
health gains in the long term. 
See Online for appendix
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interventions could, with the same total cost as the 
medium scenario, achieve a greater impact (deﬁ ned as 
more infections averted over the period 2016–50).
We repeated the analysis under alternative sets of 
assumptions whereby the development of new 
technologies was not realised, and whereby further scale-
up of existing interventions was not possible (table 2).
Model design
We developed a deterministic compartmental model of 
heterosexual HIV transmission in South Africa (full 
description and parameter values are given in Cremin 
and colleagues23 and the appendix). The model represents 
age, sex, behavioural risk, HIV infection, declining CD4 
cell count, ART scale-up, and the eight HIV prevention 
interventions, and is calibrated to South African 
demography, age-speciﬁ c and sex-speciﬁ c HIV incidence 
and prevalence, the historical scale-up of ART, 
circumcision, and patterns of condom use (appendix 
pp 1–12).24,25 We assume that almost all HIV-positive 
individuals with CD4 counts below 200 cells per μL 
present for care and receive ART (late ART).
Eight prevention methods were included in the analysis 
(table 1). Eﬃ  cacy assumptions for all interventions 
represent the underlying biological eﬃ  cacy among people 
who adhere to the method in question (appendix pp 19–22). 
For existing methods (male condoms, VMMC, early ART 
[ie, outreach testing and oﬀ ering ART to all diagnosed with 
HIV], and oral PrEP), eﬃ  cacy estimates were based on 
current data.17–22,26–28 For new PrEP products (intravaginal 
rings, long-acting antiretroviral drugs, and bNAbs), the 
eﬀ ectiveness of intravaginal rings was based on that 
observed among the women who were most highly 
adherent in the Ring Study,11 and long-acting antiretroviral 
drugs and bNAbs were assumed to have a similar 
eﬀ ectiveness to oral PrEP but potentially reached a wider 
part of the population. We included two vaccine 
Eﬃ  cacy Available from 
(medium and 
maximum 
scenarios)
Main target group Eﬀ ective coverage in main 
target group
Fixed cost (US$) Variable cost (US$)
Condoms 90%17 Now Female sex workers Constant: 29%; medium: 60%; 
maximum: 80%
$3·43–8·23 million per 
partnership type per year
$0·31–0·37 per condom
VMMC 60%18–20 Now Young men Constant: 43%; medium: 80%; 
maximum: 80%
$5 million launch (high coverage 
only) plus $27·5–36·3 million per 
population group per year
$42 per person
Early ART 85%21 Now All Constant: 0%; medium: 40%; 
maximum: 60%
$10–11·6 million per year $275–295 per person per year
Oral PrEP 90%22 Now Female sex workers, high-risk 
young women
Constant: 0%; medium: 45%; 
maximum: 80%
$5–15 million launch plus 
$3·3–11·4 million per year
$170–190 per person per year
IVR 65%11 2017 Female sex workers Constant: 0%; medium: 30%; 
maximum: 80%
$10 million launch plus $5 million 
per year
$107–115 per person per year
LA-ARVs 90% 2020 Female sex workers, high-risk 
young women
Constant: 0%; medium: 50%; 
maximum: 80%
$10 million launch plus $5 million 
per year
$180–200 per person per year
bNAbs 90% 2028 Female sex workers, high-risk 
young women
Constant: 0%; medium: 50%; 
maximum: 80%
$10 million launch plus $5 million 
per year
$190–210 per person per year
P5-like 
vaccine
50% 2024 Teenagers aged 14 years Constant: 0%; medium and 
maximum: 70%
$65 million launch plus 
$5–15 million per year
$40–60 per person per year in ﬁ rst year, 
$3·5–4·5 per person per year thereafter 
Idealised 
vaccine
70% 2030 Teenagers aged 14 years Constant: 0%; medium and 
maximum: 80%
$5 million per year throughout $50–60 per person per year in ﬁ rst year, 
$3·5–4·5 per person per year thereafter
Eﬃ  cacy refers to the protection aﬀ orded by perfect use of a product. Eﬀ ective coverage is the proportion of people who fully adhere to a product such that they beneﬁ t from its protection. Full details on 
coverage, costing, and implementation across all population sub-groups are provided in the appendix. In the Eﬀ ective coverage in main target group column, the three levels given indicate the assumptions 
under the constant, medium, and maximum scenarios. VMMC=voluntary medical male circumcision. ART=antiretroviral therapy. PrEP=pre-exposure prophylaxis. IVR=intravaginal ring. LA-ARVs=long-acting 
antiretrovirals. bNAbs=broadly neutralising antibodies.
Table 1: Summary of intervention assumptions
Condoms VMMC Early ART Oral PrEP IVR LA-ARVs bNAbs Vaccine
All interventions available
A ü ü ü ü ü ü ü ü 
High-risk technologies not brought to market
B ü ü ü ü ü X X ü
No vaccine developed
C ü ü ü ü ü ü ü X
D ü ü ü ü ü X X X
Condom interventions cannot be scaled up
E * ü ü ü ü ü ü ü
F * ü ü * * ü ü ü
Scenario A, all interventions available; scenario B, as A without LA-ARVs or bNAbs; scenario C, as A without vaccine; 
scenario D, as A without vaccine, LA-ARVs, or bNAbs; scenario E, all interventions available, condom use limited to 
constant level; scenario F, all interventions available, condom use, VMMC, and early ART limited to constant levels. 
VMMC=voluntary medical male circumcision. ART=antiretroviral therapy. PrEP=pre-exposure prophylaxis. 
IVR=intravaginal ring. LA-ARVs=long-acting antiretrovirals. bNAbs=broadly neutralising antibodies. ü=intervention is 
available at all coverage levels. X=intervention is never available. *Intervention is available only at constant scenario levels.
Table 2: Primary (A) and alternative (B–F) scenarios, where some interventions are removed from 
consideration or restricted in use 
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formulations: the P5-like vaccine is similar to the pox-
protein vaccines in development with 50% eﬃ  cacy and the 
idealised vaccine is assumed to have a higher eﬃ  cacy 
(70%) and lower attrition rate (5% compared with 10% per 
year) due to the need for less frequent booster 
administrations.16 In scenarios with vaccination available, 
we assumed that the P5-like vaccine will be available from 
2024, initially for adults and switching to teenagers aged 
14 years from 2026. The idealised vaccine will replace the 
P5-like vaccine from 2030 onwards.
For each intervention, we deﬁ ned coverage levels for 
seven population subgroups (female sex workers aged 
15–49 years, high-risk women aged 15–29 years, low-risk 
women aged 15–29 years, high-risk women aged 
30–49 years, low-risk women aged 30–49 years, high-risk 
men aged 15–49 years, low-risk men aged 15–49 years) 
under each set of scale-up assumptions (appendix 
pp 15–24). For the PrEP products (oral PrEP, intravaginal 
rings, long-acting antiretroviral drugs, and bNAbs), the 
coverage level was the proportion of persons taking PrEP 
with suﬃ  cient adherence such that they beneﬁ t fully 
from the assumed eﬃ  cacy. A product cannibalism 
assumption is also incorporated into the PrEP products’ 
coverage levels, such that the introduction of a new 
product takes some users from existing products but 
always increases total PrEP coverage (appendix p 14). The 
relative coverage of each product when implemented in 
combination is proportional to its coverage in that 
subgroup when no other PrEP product is available. When 
any vaccine is introduced, we assumed that oral PrEP, 
intravaginal rings, long-acting antiretroviral drugs, and 
bNAbs are scaled back to zero over 5 years from 2035.
Most interventions (condoms, oral PrEP, long-acting 
antiretroviral drugs, bNAbs) prioritise female sex workers 
and young women, intravaginal rings prioritise female 
sex workers, VMMC prioritises young men, and early 
ART and vaccination are assumed to have uniform 
coverage by risk, with vaccination primarily targeted to 
teenagers aged 14 years. All interventions are scaled up 
linearly over a given time period.
Late ART
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Figure 1: Eﬀ ect achievable with the full range of interventions
(A) The impact and cost of all possible interventions (grey dots), with the frontier highlighted (blue line). The medium scale-up scenario (purple dot), the optimum 
allocation point on the frontier with the same cost (green dot), and the maximum scale-up scenario (red dot) are highlighted. (B) Trajectory of HIV incidence in 
15–49-year-olds, 2016–50, for the constant scale-up, medium scale-up, optimum allocation, and maximum scale-up scenarios. (C) The level of scale-up for each 
intervention in the optimum allocation scenario. (D) The distribution of costs by intervention type, 2016–50, in the optimum allocation scenario. VMMC=voluntary 
medical male circumcision. ART=antiretroviral therapy. PrEP=pre-exposure prophylaxis. IVR=intravaginal ring. LA-ARVs=long-acting antiretrovirals. bNAbs=broadly 
neutralising antibodies.
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Costs are intended to represent the cost of fully 
delivering the intervention with the stated scale and 
eﬃ  cacy. The rationale for assumptions around ﬁ xed and 
variable costs is given in the appendix. Fixed costs (one-
time or recurring annually, but not related to scale) were 
derived from information about existing product 
launches. Variable costs (dependent on scale) were based 
on the population group in question and include the 
commodity plus a combination of service delivery, 
testing, laboratory costs, outreach and demand 
incentives, as appropriate. For all products, there is a 
step change in the ﬁ xed and variable cost when coverage 
rises above the medium scenario, such that the marginal 
cost is greater to deliver the intervention at maximum 
coverage. The total costs for all interventions were scaled 
up by a factor of 1·43 to represent the 30% of the HIV 
budget allocated to indirect costs that are not explicitly 
included here.
Throughout, we refer to each of these interventions 
with a short-hand label (eg, condoms), but the meaning 
remains that a full set of activities consistent with 
increasing the use of condoms as speciﬁ ed in our 
assumptions (eg, distribution, promotion, supply chain 
management, social marketing).
Role of the funding source
A working group of Bill & Melinda Gates Foundation 
staﬀ  (appendix p 13) together with the coauthors 
contributed to the study design and data collection. With 
the exception of coauthors, the funder had no further 
role in data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
The eﬀ ect of each intervention used in isolation was 
assessed (appendix p 48). All interventions have the 
potential to reduce HIV incidence substantially over the 
period 2016–50. Vaccination has the largest potential 
impact when scaled up to maximum coverage, followed 
by long-acting antiretroviral drugs, oral PrEP, bNAbs, 
and condoms.
The cost and eﬀ ect of all permutations of the scale-up 
of interventions were examined in the model (ﬁ gure 1). A 
frontier can be constructed across these permutations 
that shows the maximum eﬀ ect (infections averted with 
respect to the projected epidemic under the constant 
assumptions for all interventions) that can be achieved 
Condoms
VMMC
Early ART
Oral PrEP
LA-ARVs
Vaccine
A B C
IVR
bNAbs
Constant Medium Maximum
Condoms
VMMC
Early ART
Oral PrEP
LA-ARVs
Vaccine
D E F
IVR
bNAbs
Coverage level
Constant Medium Maximum
Coverage level
Constant Medium Maximum
Coverage level
Figure 2: The level of scale-up for each intervention in the optimum allocation scenario, under diﬀ erent assumptions for the availability of interventions (see table 2)
Scenario A, all interventions available; scenario B, as A without LA-ARVs or bNAbs; scenario C, as A without vaccine; scenario D, as A without vaccine, LA-ARVs, or bNAbs; scenario E, all interventions 
available, condom use limited to constant level; scenario F, all interventions available, condom use, VMMC, and early ART limited to constant levels. VMMC=voluntary medical male circumcision. 
ART=antiretroviral therapy. PrEP=pre-exposure prophylaxis. IVR=intravaginal ring. LA-ARVs=long-acting antiretrovirals. bNAbs=broadly neutralising antibodies.
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for a given cost. At the low end of the frontier, at which 
point interventions are scaled up minimally, 1·9 million 
infections would be averted and the cost of the 
programme would be US$44 billion ($1·3 billion 
per year). Most of these costs are attached to spending on 
late ART for those entering care (84%, data not shown) 
whereas the eﬀ ect is produced by increased use of 
condoms and VMMC (appendix p 45), together with the 
eﬀ ect of late ART in reducing transmission. At the high 
end, at which point all interventions are scaled up to the 
maximum possible extent, an additional 4·7 million 
infections are averted at a marginal cost of $26 billion. 
With increasing available budget, additional interventions 
are incorporated incrementally (appendix p 45). 
Condoms, VMMC, early ART, oral PrEP, and a vaccine 
are implemented at the low end of the frontier, with the 
inclusion of the intravaginal rings, long-acting 
antiretroviral drugs, and ﬁ nally bNAbs, as resources 
increase.
The medium scenario, where medium coverage is 
implemented for all interventions, implies a cost of 
$50 billion over 34 years. The conﬁ guration of inter-
ventions represented in this scenario is almost on the 
frontier, signifying that it is approaching the optimum use 
of resources (ﬁ gure 1). For the same cost, an alternative 
conﬁ guration of interventions would reduce HIV 
incidence more rapidly at ﬁ rst and generate 110 000 extra 
infections averted between 2016 and 2050 (ﬁ gure 1).
Comparison between the optimum allocation con-
ﬁ guration of interventions and the medium coverage level 
throughout (representing current programmatic aims) 
shows that increasing coverage of existing interventions 
(VMMC and early ART) to a greater extent than current 
projections would be prioritised in the optimum allocation 
scenario, together with implementing intravaginal rings 
(ﬁ gure 1). The scale-up of condoms, oral PrEP, and vaccines 
in the optimum allocation is consistent with the medium 
scenario. However, increasing coverage of long-acting 
antiretroviral drugs is only partly selected and bNAbs are 
not selected in the optimum conﬁ guration of interventions.
In the optimum allocation conﬁ guration, the largest 
amount of resources for prevention interventions is used 
for VMMC programming (28%; ﬁ gure 1). If the variable 
cost of bNAbs was reduced by just 7% it would enter the 
optimum allocation at low levels and it would require 
more than 25% reduction in variable cost to be included 
at higher coverage (appendix p 43). An additional cost of 
at least $4·5 billion would be required to push vaccination 
to below medium or maximum coverage in the optimum 
allocation (appendix p 44).
This analysis was repeated under diﬀ erent assumptions 
about the availability of interventions (ﬁ gure 2). The 
failure for long-term future products to be developed 
(scenarios B and D in table 2), or the failure for a vaccine 
to be developed (scenario C and D in table 2), does not 
substantially aﬀ ect the overall conﬁ guration of the 
programme in the respective optimum allocation for 
each. Future products do not attract substantial resources 
in the optimum allocation scenarios so their loss has 
little eﬀ ect (ﬁ gure 2). However, the ﬁ nancial resources 
released by the loss of a vaccine are outweighed by those 
needed to fund the additional ART used if there were no 
vaccine (given the higher rate of new infections), which 
also requires the removal of the intravaginal rings from 
the optimum allocation (ﬁ gure 2).
The optimum allocation of resources does change if a 
greater coverage of existing interventions cannot be 
achieved. If condom programmes are unable to achieve 
higher coverage than the current level (constant scenario), 
then the optimum allocation conﬁ guration still includes a 
strong emphasis on VMMC, early ART, intravaginal rings, 
and vaccination, and maintains a moderate emphasis on 
oral PrEP (ﬁ gure 2). If existing interventions (condoms, 
VMMC, early ART) are all unable to expand further then 
the optimum conﬁ guration of resources includes high 
levels of oral PrEP and intravaginal rings, plus a greater 
emphasis on long-acting antiretroviral drugs (ﬁ gure 2).
The biggest single determinant of overall eﬀ ect is the 
development of a vaccine (ﬁ gure 3); the expected number 
of infections averted is 35% lower without a vaccine. 
Overall eﬀ ect is also reduced by up to 23% if the scale-up 
of condom and other programmes is limited. By contrast, 
the failure of bNAbs or long-acting antiretroviral drugs to 
develop has little inﬂ uence on the overall maximum 
eﬀ ect, provided that a vaccine is developed.
A sensitivity analysis where the model was recalibrated 
for Cross River State, Nigeria, shows a diﬀ erent optimum 
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Figure 3: Maximum impact (HIV infections averted 2016–50) achievable with 
the resources implied in the medium scenario, under diﬀ erent assumptions for 
the availability of interventions (see table 2)
Scenario A, all interventions available; scenario B, as A without long-acting 
antiretrovirals or broadly neutralising antibodies; scenario C, as A without vaccine; 
scenario D, as A without vaccine, long-acting antiretrovirals, or broadly neutralising 
antibodies; scenario E, all interventions available, condom use limited to constant 
level; scenario F, all interventions available, condom use, voluntary medical male 
circumcision, and early antiretroviral therapy limited to constant levels.
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allocation (for details of calibration see appendix 
pp 4–6, 46). Cross River State has a concentrated HIV 
epidemic with lower overall HIV prevalence than 
South Africa, a smaller group at highest risk driving the 
epidemic, and very high VMMC coverage.29 In this 
setting, the budget available to allocate across inter-
ventions is much lower ($5·6 billion), meaning that 
fewer interventions are aﬀ ordable and interventions that 
target those at highest risk of infection are preferred. In 
the optimum allocation, condoms, intravaginal rings, 
and vaccination are all implemented at maximum levels, 
with all other interventions remaining constant.
Discussion
Overall, this analysis highlights the need to exploit fully 
the prevention interventions available today. We ﬁ nd that 
with a budget consistent with a reasonable set of aims 
(ie, the budget of the medium scenario), the greatest 
eﬀ ect is generated if prevention eﬀ orts focus on high 
coverage of VMMC and early ART programming, use of 
intravaginal rings particularly by sex workers and, later, 
achieving high coverage of a vaccine. The single most 
crucial intervention is the development of a vaccine. 
However, if it is not possible to scale up existing 
interventions to the extent envisioned here, the use of 
PrEP products would become more important to 
generate the most impact possible.
In this light, a focus on removing the barriers that exist 
to greater uptake of VMMC, together with early ART, 
especially, is the priority. An exclusive focus on the 
development and scaling up of new products, which 
themselves will have to confront similar barriers, would 
not generate the greatest eﬀ ect. However, the widening 
range of interventions provides opportunities to maintain 
eﬀ ect by compensating for failures in other potential 
interventions.
There are two major limitations to this analysis. First, 
the representation of product coverage in the model 
includes three discrete patterns over the diﬀ erent 
population sub-groups rather than an exploration of all 
the possible combinations. Although these represent 
expectations among the authors and the technical group 
(appendix p 13), this could aﬀ ect the cost–beneﬁ t proﬁ le 
of interventions. For example, products assumed to be 
targeted to high-risk groups (eg, condom use, PrEP 
products) might seem more attractive than those that 
have uniform coverage by risk or age (eg, early ART), 
and if interventions could be scaled-up diﬀ erentially by 
age or risk group, a diﬀ erent combination might have 
been identiﬁ ed in this analysis as a priority. 
Furthermore, some interventions could have already 
reached saturation—for example, condom prevention 
programmes in hyperendemic settings have been 
aiming to increase condom use for many years with 
mixed success.
Second, cost assumptions in the model are not 
perfectly informed by data. This limitation is inevitable 
when making projections for scale-up of future 
interventions. However, we aimed to make consistent 
assumptions across the interventions for the analysis to 
be directionally correct; and the total spending in the 
model for recent years is similar to South Africa HIV 
programme costs.30,31 Estimated condom and VMMC 
costs are higher in this cost model than the recent 
South African HIV and TB Investment Case, but the 
results are broadly consistent with both identiﬁ ed as 
important priorities.31 We do not include research and 
development costs but these might also be substantial; 
neither do we include the potential development of drug 
resistance or the extra treatment costs these could incur.
The analysis focuses on South Africa, but the sensitivity 
analysis for a lower prevalence setting shows that the 
results are highly dependent on the epidemic setting. 
The setting will determine budget level and relative 
eﬀ ectiveness of the diﬀ erent interventions according to 
the size and level of risk across the diﬀ erent population 
groups. This study complements substantial other 
modelling work about the allocation of resources in 
South Africa by including future interventions and 
taking a long-term perspective.31,32 It adds to a growing 
body of literature on resource allocation for HIV 
prevention, which highlights the need to account for 
local epidemiology to maximise the eﬃ  ciency of HIV 
prevention planning.6,33–37
This analysis represents an interrogation of the 
information available today, with a view on the evidence 
of interventions and risk and beneﬁ ts that is to an extent 
dependent upon the perspective of the authors. The 
intention would be that such an analysis would be 
updated as new information becomes available. A 
strategic approach in which limited resources are used to 
maximise prevention eﬀ ect would focus on strengthening 
the scale-up of existing interventions, while urgently 
pursuing a workable vaccine and developing other 
approaches that can be used if increasing use of existing 
interventions is limited.
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